RxDoctor Payments Data

Roberto Guerra del Castillo, MD

Cardiovascular Disease · Miami Beach, FLNPI 1003156209

Payments from drug & device makers

$997in general payments, 2019–2025

Across 29 payments — averaging $34.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$289
  • Pfizer$222
  • AbbVie$214
  • Indivior Inc.$97
  • Teva Pharmaceuticals USA, Inc.$50
  • Novartis$49
  • plus $76 from 3 others

What the payments were for

  • Food & beverage$997100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$997 in reported general payments places this provider in the 25th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,252,286
Medicare patients
191
Services billed
1,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide34$35,886
EliquisApixaban29$22,541
SynjardyEmpagliflozin/Metformin Hcl14$12,174
VascepaIcosapent Ethyl28$11,653
XareltoRivaroxaban19$10,719
FarxigaDapagliflozin Propanediol17$9,602
EntrestoSacubitril/Valsartan14$8,683
LantusInsulin Glargine,hum.Rec.Anlog12$881
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip29$819
Atorvastatin Calcium92$698
Candesartan Cilexetil19$602
Famotidine55$555
Omega-3 Acid Ethyl Esters17$519
Testosterone Cypionate12$492
Gabapentin41$464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$222$22,54129 claims
Johnson & JohnsonXarelto$289$10,71919 claims
NovartisEntresto$49$8,68314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →